recent post

SECL's CSR initiative completes heart surgeries for 20 children

November 1, 2024
recent post

Parexel names Keri Mattox as Chief Business Officer

recent post

CARE Hospitals inaugurates multi-specialty clinic for international patients in Tolichowki, Hyderabad

October 31, 2024
recent post

FICCI to organise 18th edition FICCI HEAL on November 5-6, 2024

October 30, 2024
recent post

Thermo Fisher Scientific partners with Government of Telangana

GE HealthCare collaborates with Novo Nordisk

GE HealthCare collaborates with Novo Nordisk

To advance novel non-invasive treatment for Type 2 diabetes and obesity with ultrasound GE HealthCare announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral-focussed ultrasound (PFUS). This is a novel technology that has the potential to specifically regulate metabolic function in the body using ultrasound and may support the treatment of chronic diseases such as type 2 diabetes and obesity. PFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the nervous system to stimulate a response that may be able to treat disease. Pre-clinical proof of concept and initial early-stage clinical research suggests that it may impact glucose metabolism in people with diabetes via personalised ultrasound stimulation of nerve pathways. If validated with further clinical evidence, PFUS could represent a non-pharmacologic approach to normalise blood glucose levels in people with type 2 diabetes. The existing technology was developed by a team of scientists at GE HealthCare’s HealthCare Technology and Innovation Center, formerly part of the GE Research Center. “In an era where diabetes is increasing around the globe, we are enthusiastic about the potential for ultrasound to help people live healthier lives,” said Roland Rott, President and CEO, Ultrasound, GE HealthCare. “This collaboration with Novo Nordisk opens a path to evolve ultrasound from a means of screening and diagnosis into therapy, as well. We are eager to validate and further develop this potentially groundbreaking science, as we strive to offer patients alternative treatment options for chronic diseases.” “We look forward to exploring the potential impact this technology could have on treating people with type 2 diabetes and obesity, as significant unmet needs remain in these diseases despite recent advances in care,” said Martin Holst Lange, Executive Vice President and Head of Development at Novo Nordisk. “Although early, the possibilities of using ultrasound for therapeutic purposes are compelling and we welcome our collaboration with GE HealthCare in this truly novel area.” As part of the collaboration, GE HealthCare and Novo Nordisk will contribute their respective expertise in ultrasound medical technology and metabolic disease treatment and management as both parties work together to develop a PFUS solution to improve patient care, building upon the extensive foundational research done to date by the GE HealthCare team.